Skip to main content
NIH funding notice PA-14-136

Prevention and Treatment of Substance Using Populations with or at Risk for HCV (R21)

Closed on May 7, 2017.

Posted
March 3, 2014
Close date
May 7, 2017
Activity codes
Not stated on the notice page
Institutes taking part
Not stated on the notice page

Read the notice on Grants.gov · NIH Guide page

The notices it replaced

Its page was not saved, so the notices it replaced are not known.

Who won it before

2 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $404,699 in first-year total cost, median $202,350.

Most frequent study sections

  1. AIDS Clinical Studies and Epidemiology Study Section[ACE]1
  2. Behavioral Medicine, Interventions and Outcomes Study Section[BMIO]1

Most frequent institutions

  1. MAGEE-WOMEN'S RES INST AND FOUNDATION1
  2. YALE UNIVERSITY1
Competing awards under PA-14-136 and the notices it replaced
FYProjectPIsInstitutionFirst-year costStudy section
2016Modeling HCV/HIV transmission and Treatment as Prevention in U.S. Networks of People Who Inject Drugs1R21DA041953-01ALTICE, FREDERICK LEWISYALE UNIVERSITY, CT$221,514ACE
2015Facilitating HCV Treatment through Tailored Prenatal Care for HCV Infected, Substance using Pregnant Women1R21DA039345-01KRANS, ELIZABETH EMAGEE-WOMEN'S RES INST AND FOUNDATION, PA$183,185BMIO

Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-10-0.1.1. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.

ScienceDex for faculty

Your academic CV and NIH biosketch

Make your CV in your school's format and your NIH biosketch from it, then download both as Word files.